Evidence map›Paper›PMID 27075025›Full record

ArticleHead and neck pathology2016

A Case of Primary Mammary Analog Secretory Carcinoma (MASC) of the Thyroid Masquerading as Papillary Thyroid Carcinoma: Potentially More than a One Off.

S Reynolds, M Shaheen, G Olson, M Barry, J Wu, T Bocklage

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Head and neck pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Newly described salivary gland tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S ReynoldsDepartment of Pathology, University of New Mexico School of Medicine (UNM SOM), MSC08-4640, Albuquerque, NM, 87131-0001, USA.
M ShaheenDivision of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine (UNM SOM), Albuquerque, NM, USA.
G OlsonDivision of Otolaryngology, Department of Surgery, University of New Mexico School of Medicine (UNM SOM), Albuquerque, NM, USA.
M BarryDepartment of Pathology, University of New Mexico School of Medicine (UNM SOM), MSC08-4640, Albuquerque, NM, 87131-0001, USA.
J WuDepartment of Pathology, University of New Mexico School of Medicine (UNM SOM), MSC08-4640, Albuquerque, NM, 87131-0001, USA.
T BocklageDepartment of Pathology, University of New Mexico School of Medicine (UNM SOM), MSC08-4640, Albuquerque, NM, 87131-0001, USA. tbocklage@salud.unm.edu.
University of New Mexico · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the second reported mammary analog secretory carcinoma (MASC) apparently arising in the thyroid and propose a potential close relationship to ETV6-NTRK3 fusion papillary thyroid carcinoma. The patient, a 36 year old woman, presented with a neck mass of 1 year's duration. Imaging studies showed a tumor involving most of the thyroid with enlarged regional lymph nodes. FNA biopsy yielded a diagnosis of "papillary thyroid carcinoma". Resection revealed a 4.5 cm infiltrative tumor. Final diagnosis was "papillary thyroid carcinoma (PTC) consistent with diffuse sclerosing variant" with positive lymph nodes (2+/4) and margins. Histologic features included mixed microcystic, solid, follicular and papillary architecture, prominent nucleoli, abundant nuclear grooves and rare nuclear pseudo-inclusions. Despite radioactive iodine, radiotherapy and multiagent chemotherapy, the patient progressed over 6 years with local recurrence and additional lymph node involvement finally developing widespread distant metastases. Prompted by the breast carcinoma-like histopathology of a metastasis, immunohistochemical staining was performed and revealed strong expression of GATA3 and mammaglobin with no reactivity for thyroglobulin or TTF-1. The original tumor was then tested and showed the same immunoprofile. RT-PCR confirmed the presence of an ETV6-NTRK3 fusion consistent with a diagnosis of MASC. Our patient's clinical, imaging and morphologic features remarkably mimicked papillary thyroid carcinoma. At the molecular level, the ETV6-NTRK3 fusion in this patient involved exons reported in the rare "papillary thyroid carcinoma" with this translocation. Given the immunophenotype of this case, it is possible that at least some ETV6-NTRK3 fusion positive PTC are actually MASC masquerading as papillary thyroid carcinoma.

Indexed as

Biopsy, Fine-NeedleDiagnostic ErrorsAdultBiomarkers, TumorCarcinomaCarcinoma, PapillaryETS Translocation Variant 6 ProteinFemaleHumansImmunohistochemistryMammary Analogue Secretory CarcinomaOncogene Proteins, FusionReceptor, trkCReverse Transcriptase Polymerase Chain ReactionThyroid Cancer, PapillaryThyroid NeoplasmsBiomarkers, TumorETS Translocation Variant 6 ProteinETV6-NTRK3 fusion protein, humanOncogene Proteins, FusionReceptor, trkCETV6-NTRK3 fusionGeneticsMASCPapillary thyroid carcinomaThyroid carcinoma

Identifiers

PMID27075025
PMCPMC4972767
OpenAlexW2337537712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.